{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enoxaparin+Placebo", "query": { "intervention": "Enoxaparin Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enoxaparin+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T02:49:22.409Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00423319", "title": "Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Deep Vein Thrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Enoxaparin-matching placebo", "type": "DRUG" }, { "name": "Apixaban-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5407, "start_date": "2007-03", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2014-05-14", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423319" }, { "nct_id": "NCT00721760", "title": "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Enoxaparin sodium", "type": "DRUG" }, { "name": "Semuloparin sodium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1003, "start_date": "2008-07", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00721760" }, { "nct_id": "NCT00362232", "title": "Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Placebo: tablet of Rivaroxaban", "type": "DRUG" }, { "name": "Placebo: syringes of Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3148, "start_date": "2006-06", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00362232" }, { "nct_id": "NCT01863134", "title": "Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Non ST Elevation Myocardial Infarction" ], "interventions": [ { "name": "Eptifibatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of Silesia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 140, "start_date": "2005-01", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2013-10-31", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01863134" }, { "nct_id": "NCT00718224", "title": "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Semuloparin sodium", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1150, "start_date": "2008-07", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00718224" }, { "nct_id": "NCT02271113", "title": "Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "GMI-1271", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Enoxaparin Sodium (Lovenox®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlycoMimetics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2014-10", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02271113" }, { "nct_id": "NCT01583218", "title": "Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism (VTE)" ], "interventions": [ { "name": "Betrixaban", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 7513, "start_date": "2012-03", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01583218" }, { "nct_id": "NCT00345618", "title": "Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Embolism", "Thrombosis" ], "interventions": [ { "name": "Idrabiotaparinux sodium", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Placebo (for idrabiotaparinux sodium)", "type": "DRUG" }, { "name": "Avidin", "type": "DRUG" }, { "name": "Placebo (for warfarin)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3202, "start_date": "2006-06", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345618" }, { "nct_id": "NCT03083704", "title": "A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Andexanet alfa (Gen 1 Process 2)", "type": "BIOLOGICAL" }, { "name": "Apixaban 5 MG", "type": "DRUG" }, { "name": "Rivaroxaban 20 MG", "type": "DRUG" }, { "name": "Enoxaparin sodium", "type": "DRUG" }, { "name": "Edoxaban 60 MG", "type": "DRUG" }, { "name": "Andexanet alfa (Gen 2)", "type": "BIOLOGICAL" }, { "name": "Andexanet alfa (Gen 1 Process 3)", "type": "BIOLOGICAL" }, { "name": "Apixaban 10 MG", "type": "DRUG" }, { "name": "Rivaroxaban 10 MG", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 153, "start_date": "2017-02-26", "completion_date": "2017-09-28", "has_results": false, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03083704" }, { "nct_id": "NCT00643201", "title": "Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" }, { "name": "warfarin", "type": "DRUG" }, { "name": "Placebo for apixaban", "type": "DRUG" }, { "name": "Placebo for enoxaparin", "type": "DRUG" }, { "name": "Placebo for warfarin", "type": "DRUG" }, { "name": "apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5614, "start_date": "2008-07", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-09-04T02:49:22.409Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Banning", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00643201" } ] }